Thyrocare Technologies Limited (THYROCARE.NS)
Thyrocare Technologies Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Navi Mumbai, MA, IN. The stock last traded at $624.05, up 2.98% on the session, giving a market capitalisation of $99.33B. Its beta of 0.47 implies it has historically moved less than the broad market.
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.
Thyrocare Technologies Limited is most often compared with the following Healthcare names: